Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Macular Edema (Jan 2021)

Posted by Matt Breese on Jan 22, 2021

Find me on:

According to our recent payer coverage analysis for macular edema treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for macular edema treatments shows that under the pharmacy benefit, almost 37% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Macular Edema-1Q2021Data snapshot as of Q1 2021

Trends: In August 2019, the FDA granted approval to Eylea (aflibercept) as a prefilled syringe. It remains available in the original single-dose vial for which it was approved in November 2011. The Regeneron Pharmaceuticals, Inc. product is indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy.  

To read the full Reality Check on Macular Edema treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing